FarmaKology Newsletter - Issue #68
Longevity Biotech is developing new therapeutic drug candidates, which may have direct clinical impacts on patients lives. All of our programs are based on our Hybridtide peptide scaffold technology. Hybridtides are designed for long-acting oral administration.
Evotec and Chinook Therapeutics enter into a strategic collaboration to discover and develop novel precision medicines for chronic kidney diseases
Evotec SE and Chinook Therapeutics, Inc. today announced a strategic collaboration focused on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases (“CKD”). Based on Evotec’s proprietary comprehensive molecular datasets from thousands of patients across chronic kidney diseases of multiple underlying etiologies, Chinook and Evotec will jointly identify, characterise and validate novel mechanisms and discover and develop precision medicines.
New vaccine to 'provide 2-year protection'
An adenovirus vector vaccine against COVID-19 by CanSino Biologics is projected to provide protection for two years if a booster shot is administered, said a scientist who played a key role in the vaccine's development. The Chinese National Medical Products Administration granted conditional market approval to the vaccine on Thursday. The vaccine, called Ad5-nCoV, has an efficacy rate of 65.7 per cent at preventing symptomatic cases and is 90.9 per cent effective in preventing severe disease with a single injection, according to an interim analysis of late-stage human trials released in February.
Eurofins Announces the launch of an At-Home COVID-19 PCR Test kit available direct to consumers, without prescription
Eurofins’s Clinical Enterprise, Inc. announces that it has received US Food and Drug Administration Emergency Use Authorization (EUA) for a direct-to-consumer version of its EmpowerDX COVID-19 Home Collection Kit. The Eurofins at-home COVID-19 nasal PCR kit is among the first over-the-counter at-home test kits for SARS-CoV-2 to receive EUA. With this authorization, Eurofins is able to sell the test kit directly to consumers without a prescription.
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use - First Single-Shot Vaccine in Fight Against Global Pandemic
Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older.
Research & Study
Study finds the use of genomic testing in infection control could save 650 lives a year in Queensland
Researchers determine the reason for ineffectiveness of current drug therapies
Doctors give wrong antibiotics for UTIs nearly 50% of the time
Stream Cowen Insights | RESET-ing The Treatment Paradigm For Mental Health With Pear Therapeutics by Cowen from desktop or your mobile device